HEPATOCELLULAR CARCINOMA (HCC)
Clinical trials for HEPATOCELLULAR CARCINOMA (HCC) explained in plain language.
Never miss a new study
Get alerted when new HEPATOCELLULAR CARCINOMA (HCC) trials appear
Sign up with your email to follow new studies for HEPATOCELLULAR CARCINOMA (HCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Liver cancer drug trial halted early – but holds promise for High-Risk patients
Disease control TerminatedThis study looked at whether the drug cadonilimab could help keep liver cancer from returning after surgery in patients at high risk of recurrence. It involved 45 adults who had their liver cancer completely removed. The trial was stopped early, but the goal was to see if the dru…
Matched conditions: HEPATOCELLULAR CARCINOMA (HCC)
Phase: PHASE2 • Sponsor: Guangxi Medical University • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Experimental cancer drug tested in advanced tumors – study halted early
Disease control TerminatedThis early-stage study tested an experimental drug called INCB062079 in 25 people with advanced liver cancer (hepatocellular carcinoma) and several other solid tumors. The main goal was to check the drug's safety and find the highest dose people could tolerate. The study was term…
Matched conditions: HEPATOCELLULAR CARCINOMA (HCC)
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 05, 2026 11:56 UTC